Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1

References

• Al-Hadiya BM. (2005). Niclosamide: comprehensive profile. Profiles Drug Subst Excip Relat Methodol 32:67–96
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al., Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
   PubMed Web of Science ®Google Scholar
• Chang YW, Yeh TK, Lin KT, et al. (2006). Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats. J Food Drug Anal 14:329–33
   Web of Science ®Google Scholar
• Costa A, Sarmento B, Seabra V. (2014). An evaluation of the latest in vitro tools for drug metabolism studies. Expert Opin Drug Metab Toxicol 10:103–19
   PubMed Web of Science ®Google Scholar
• Court MH. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104–16
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Houston JB, Galetin A. (2011). Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864–73
   PubMed Web of Science ®Google Scholar
• Dawson VK, Schreier TM, Boogaard MA, Gingerich WH. (1999). Uptake, metabolism, and elimination of niclosamide by fish. In: Smith DJ, Gingerich WH, Beconi-Barker MG, eds. Xenobiotics in fish. Springer, 167–76
   Google Scholar
• Douch PG, Gahagan HM. (1977). The metabolism of niclosamide and related compounds by Moniezia expansa, Ascaris lumbricoides var suum, and mouse- and sheep-liver enzymes. Xenobiotica 7:301–7
   PubMed Web of Science ®Google Scholar
• Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2010). Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11:678–85
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–91
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Krausz KW, Nagaoka K, et al. (2014). In vivo effects of the pure aryl hydrocarbon receptor antagonist GNF-351 after oral administration are limited to the gastrointestinal tract. Br J Pharmacol 171:1735–46
   PubMed Web of Science ®Google Scholar
• Fonseca BD, Diering GH, Bidinosti MA, et al. (2012). Structure–activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 287:17530–45
   PubMed Web of Science ®Google Scholar
• Fujita K, Sparreboom A. (2010). Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 5:209–17
   PubMedGoogle Scholar
• Gao H, Steyn SJ, Chang G, Lin J. (2010). Assessment of in silico models for fraction of unbound drug in human liver microsomes. Expert Opin Drug Metab Toxicol 6:533–42
   PubMed Web of Science ®Google Scholar
• Gertz M, Houston JB, Galetin A. (2011). Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633–42
   PubMed Web of Science ®Google Scholar
• Griffiths LA, Facchini V. (1979). The major metabolites of niclosamide: identification by mass spectrometry. In: Frigerio A, ed. Recent developments in mass spectrometry in biochemistry and medicine. Vol. 2. Springer, 121–6
   Google Scholar
• Hallifax D, Foster JA, Houston JB. (2010). Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150–61
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724–6; author reply 727
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Tracy TS. (2002). Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355–62
   PubMed Web of Science ®Google Scholar
• Imperi F, Massai F, Ramachandran Pillai C, et al. (2013). New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob Agents Chemother 57:996–1005
   PubMed Web of Science ®Google Scholar
• Jin Y, Lu Z, Ding K, et al. (2010). Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 70:2516–27
   PubMed Web of Science ®Google Scholar
• Kassahun K, Mattiuz E, Franklin R, Gillespie T. (1998). Olanzapine 10-N-glucuronide: a tertiary N-glucuronide unique to humans. Drug Metab Dispos 26:848–55
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–15
   PubMed Web of Science ®Google Scholar
• Li Y, Li PK, Roberts MJ, et al. (2014). Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett 349:8–14
   PubMed Web of Science ®Google Scholar
• Liu W, Liu H, Sun H, et al. (2014b). Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica 44:455–64
   PubMed Web of Science ®Google Scholar
• Liu H, Sun H, Lu D, et al. (2014a). Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence. Xenobiotica 44:696–707
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Bock KW, Burchell B, et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677–85
   PubMed Web of Science ®Google Scholar
• Manevski N, Moreolo PS, Yli-Kauhaluoma J, Finel M. (2011). Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9. Drug Metab Dispos 39:2117–29
   PubMed Web of Science ®Google Scholar
• Nagar S, Blanchard RL. (2006). Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 38:393–409
   PubMed Web of Science ®Google Scholar
• Nakajima M, Nakamura S, Tokudome S, et al. (1999). Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381–91
   PubMed Web of Science ®Google Scholar
• Nakamura A, Nakajima M, Yamanaka H, et al. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461–4
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR. (2005). Cytochrome P450: structure, mechanism, and biochemistry. Springer Science & Business Media
   Google Scholar
• Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6
   PubMed Web of Science ®Google Scholar
• Pan JX, Ding K, Wang CY. (2012). Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer 31:178–84
   PubMed Web of Science ®Google Scholar
• Park SJ, Shin JH, Kang H, et al. (2011). Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. BMB Rep 44:517–22
   PubMed Web of Science ®Google Scholar
• Pastrakuljic A, Tang BK, Roberts EA, Kalow W. (1997). Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53:531–8
   PubMed Web of Science ®Google Scholar
• Poulin P, Haddad S. (2011). Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J Pharm Sci 100:4501–17
   PubMed Web of Science ®Google Scholar
• Prentis RA, Lis Y, Walker SR. (1988). Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985). Br J Clin Pharmacol 25:387–96
   PubMed Web of Science ®Google Scholar
• Reid JM, Kuffel MJ, Miller JK, et al. (1999). Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 5:2192–7
   PubMed Web of Science ®Google Scholar
• Rowland A, Elliot DJ, Knights KM, et al. (2008). The “albumin effect” and in vitro–in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870–7
   PubMed Web of Science ®Google Scholar
• Seo KA, Kim HJ, Jeong ES, et al. (2014). In vitro assay of six UDP-glucuronosyltransferase isoforms in human liver microsomes, using cocktails of probe substrates and liquid chromatography–tandem mass spectrometry. Drug Metab Dispos 42:1803–10
   PubMed Web of Science ®Google Scholar
• Shet MS, McPhaul M, Fisher CW, et al. (1997). Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos 25:1298–303
   PubMed Web of Science ®Google Scholar
• Shimada H, Eto M, Ohtaguro M, et al. (2010). Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol 24:230–4
   PubMed Web of Science ®Google Scholar
• Sun H, Wang H, Liu H, et al. (2014). Glucuronidation of capsaicin by liver microsomes and expressed UGT enzymes: reaction kinetics, contribution of individual enzymes and marked species differences. Expert Opin Drug Metab Toxicol 10:1325–36
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Birkett DJ, Veronese ME, et al. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401–7
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Weemhoff JL, Bedir E, et al. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56:1039–44
   PubMed Web of Science ®Google Scholar
• Wang AM, Ku HH, Liang YC, et al. (2009). The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J Cell Biochem 106:682–92
   PubMed Web of Science ®Google Scholar
• Wang LZ, Ramirez J, Yeo W, et al. (2013). Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One 8:e54522
   PubMed Web of Science ®Google Scholar
• Wells PG, Mackenzie PI, Chowdhury JR, et al. (2004). Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32:281–90
   PubMed Web of Science ®Google Scholar
• Wu B, Dong D, Hu M, Zhang S. (2013). Quantitative prediction of glucuronidation in humans using the in vitro–in vivo extrapolation approach. Curr Top Med Chem 13:1343–52
   PubMed Web of Science ®Google Scholar
• Zhou J, Tracy TS, Remmel RP. (2010). Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38:431–40
   PubMed Web of Science ®Google Scholar
• Zhou SF, Yang LP, Zhou ZW, et al. (2009). Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 11:481–94
   PubMed Web of Science ®Google Scholar
• Zhu LL, Ge GB, Zhang HB, et al. (2012). Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 40:529–38
   PubMed Web of Science ®Google Scholar